Overview
- Trump declared himself the “affordability president” in a Nov. 29 Truth Social post, crediting “favored nations” status for drug price drops of 500% to 700%.
- News outlets and fact-checkers challenged the math and documentation of the claim, noting he has made similar percentage assertions for months.
- The White House cites recent industry agreements, including GLP‑1 pricing arrangements with Novo Nordisk and Eli Lilly and an AstraZeneca pledge to match its lowest global prices for Medicaid.
- Medicare recently announced negotiated prices for 15 high‑cost drugs averaging 36% lower, or roughly $8.5 billion in savings, indicating targeted reductions rather than broad across‑the‑board cuts.
- Pfizer’s CEO said the company received a three‑year tariff grace period tied to new U.S. manufacturing investment, and Trump’s post drew online mockery such as Stocktwits’ “Math is hard” response as he leans into an affordability message after GOP election losses.